- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Westminster Today
By the People, for the People
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
Stansky brings 40 years of investment management and healthcare experience to TriSalus's board.
Published on Feb. 10, 2026
Got story updates? Submit your updates here. ›
TriSalus Life Sciences, an oncology-focused medical technology company, has announced that Michael P. Stansky has been appointed to the company's Board of Directors, effective February 4, 2026. Stansky brings 40 years of investment management and healthcare experience, having served on the boards of numerous public and private healthcare companies.
Why it matters
The appointment of Stansky to TriSalus's board is expected to provide valuable expertise and guidance as the company continues to execute on its strategic and growth objectives, particularly in the areas of capital markets, governance, and value creation.
The details
Stansky most recently served as a Managing Director at Tudor Investment Corporation, where he helped form the firm's equity investment group and was responsible for long/short equity, crossover, and venture investments. Prior to Tudor, he was an analyst and portfolio manager at Wellington Management Company. Stansky currently serves on the board of directors of several innovative healthcare companies, including Insightec and Momentis Surgical. Past board positions include Mako Surgical, OrthoSensor, and Transmedics.
- Stansky's appointment to the TriSalus Board of Directors was effective on February 4, 2026.
The players
Michael P. Stansky
A veteran healthcare investor with 40 years of experience in investment management and serving on the boards of numerous public and private healthcare companies.
Mats Wahlstrom
The Chairman of TriSalus Life Sciences.
Arjun 'JJ' Desai
A former member of the TriSalus Board of Directors who has resigned from the board.
TriSalus Life Sciences
An oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors.
What they’re saying
“On behalf of the Board, we thank JJ Desai for his leadership, thoughtful perspective, and commitment to TriSalus during a critical period of the Company's development. JJ has been a valued partner in advancing our strategy, and we wish him continued success in his future endeavors.”
— Mats Wahlstrom, Chairman of TriSalus (biospace.com)
“We are pleased to welcome Michael Stansky to the TriSalus Board. Michael has a strong track record as an investor and board member across the healthcare landscape. His deep experience in capital markets, governance, and value creation will be a meaningful asset as TriSalus continues to execute on its strategic and growth objectives.”
— Mats Wahlstrom, Chairman of TriSalus (biospace.com)
“I am honored to join the TriSalus Board at this important stage in the Company's evolution. TriSalus's PEDD™ platform has the potential to meaningfully improve outcomes for patients with solid tumors, and I look forward to contributing my experience to support the Company's long-term vision and shareholder value creation.”
— Michael Stansky (biospace.com)
The takeaway
The appointment of veteran healthcare investor Michael Stansky to TriSalus Life Sciences' Board of Directors is expected to provide valuable expertise and guidance as the company continues to advance its innovative drug delivery technologies and immunotherapies to improve outcomes for patients with solid tumors.
